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Abstract
Background: Multiple sclerosis (MS), Hashimoto's disease and Graves' disease are autoimmune
diseases that may share similar pathogenic mechanisms. The co-occurrence rates and demographic
characteristics of Graves' disease and Hashimoto's disease (HT) in our MS population are
compared with the general population.
Methods: The prevalence of thyroid disease in our MS patients was determined by chart review
and survey. Previous diagnosis of thyroid disease, age at diagnosis, treatment used, and about the
use of disease modifying medications used to treat their MS were asked. Chart reviews were used
to estimate the population prevalence of Graves' disease and Hashimoto's disease and to estimate
the demographics of patients with thyroid disease.
Results: A significant co-occurrence of Graves' disease with MS (p = 0.002), and a non-significant
co-occurrence of Hashimoto's disease were noted (p = 0.097). No difference in the age of onset
or gender of thyroid disease in MS patients compared to the general population was found.
Conclusion: There is a significant co-occurrence in patients with MS and Graves' disease, and a
trend to co-occurrence in patients with MS and Hashimoto's disease. There are no differences in
the demographics of patients with thyroid disease in our MS patients compared to the general
population.
Introduction
Autoimmune diseases, sometimes defined as a clinical syn-
drome caused by the activation of T cells or B cells, or both, in
the absence of an ongoing infection or other discernible cause
[1], comprise a heterogeneous group of disorders wherein
alterations in the immune system may result in a spec-
trum of disease that either targets specific organs or affects
the body systemically. Even though each purported
autoimmune disease affects disparate organs and systems,
the existence of fundamental pathophysiological mecha-
nisms is hypothesized. Recent such epidemiological stud-
ies have shown an increased statistical susceptibility for
people with one autoimmune disease to develop another
[2-5]. This provocative increased relative risk of acquiring
a second autoimmune disease may be due to a genetic sus-
ceptibility that affects both diseases, an environmental
trigger that initiates both diseases, the alteration of the
body's homeostasis by one disease that creates suscepti-
bility to another, or some as yet undefined shared mecha-
nism.
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Some studies have shown that autoimmune diseases
"cluster together"[5]. Specifically, several studies have
shown an increased co-occurrence of MS with Hashim-
oto's thyroiditis (HT) as compared to the general popula-
tion [3,4,6] as well as an increased co-occurrence of MS
with Graves' disease [7] while other have not [2]. No com-
ment on the age of onset of thyroid disease in MS patients
compared with the general population has been previ-
ously made. Some studies have shown that the risk of
acquiring autoimmune thyroid disease has been shown to
increase after treatment with some MS disease modifying
agents [8]. The population co-occurrence of MS and
autoimmune thyroid disease has not been studied after
accounting for previous disease modifying therapy[5].
We have undertaken an epidemiological study of MS and
autoimmune thyroid diseases in Newfoundland and Lab-
rador (NL) to elucidate some of the epidemiological fea-
tures of any co-occurrence found amongst these diseases.
Presumably, if one is susceptible to more than one dis-
ease, then features such as clinical onset of disease may be
seen earlier in those more susceptible, especially if one
disease provokes another.
NL, with its centralized and comprehensive medical
records system and its unique population [9,10] is an
excellent place to perform such epidemiological studies.
The prevalence of MS was previously determined [11]
with near complete case ascertainment. However, the
prevalence of thyroid disease in the general population of
NL was unknown. Therefore, an estimate of the preva-
lence of thyroid disease in NL was also undertaken in
order to compare the prevalence of thyroid disease in the
MS population with the prevalence of thyroid disease in
the general NL population and to compare their demo-
graphics.
Methods
An incidence and prevalence study for the Canadian prov-
ince of Newfoundland and Labrador has recently been
completed (Dec 31, 2001), demonstrating an MS popula-
tion prevalence for MS of 94.4 per 100,000 [11]. A data-
base was created with patient information for 493
confirmed living cases [11]. Complete chart reviews were
conducted on each confirmed case to determine if these
patients had concomitant thyroid disease. Careful chart
reviews were performed in the patients' neurology charts
and their inpatient hospital charts. As well, electronic
searches through the hospital information systems for the
four main community hospitals were conducted for both
case ascertainment and diagnosis confirmation of MS and
thyroid disease. MS diagnosis type, thyroid diagnosis
type, and age at onset of disease were captured.
In October 2003, a survey was mailed to the living diag-
nosed patients from the prevalence study whose current
addresses could be confirmed, with a subsequent mailer
to those that did not initially respond after 6 weeks. The
survey asked questions relating to concomitant thyroid
disease and age of initial symptoms (Table 1). This survey
and all case searches were conducted with the approval of
the Human Investigations Committee of Memorial Uni-
versity.
To determine the prevalence of thyroid disease in the gen-
eral population, a representative population sample was
sought whereby complete case histories were taken on
clinic patients and bias towards a known predisposition
to thyroid disease was minimized. The general neurology
clinic was used for case ascertainment of thyroid disease
in a representative general population after it was deter-
mined by thorough literature search that there is no
known association of thyroid disease in patients with pri-
Table 1: Survey questions related to thyroid disease
Have you ever been treated for thyroid disease in the past?
Yes No
If yes (multiple yes answers are possible)
Was this called Graves' disease? No Yes
Was this called Hashimoto's disease? No Yes
Was this called hyperthyroidism? No Yes
Was this called hypothyroidism? No Yes
Did you ever take Synthroid? No Yes
Did you ever take Eltroxin? No Yes
Did you ever take propylthiouricil? No Yes
Did you ever take methimazole? No Yes
Did you ever have radiation treatment for your thyroid? No Yes
At what age were you diagnosed with any of the above? ________ years oldJournal of Autoimmune Diseases 2005, 2:9 http://www.jautoimdis.com/content/2/1/9
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mary headache disorders or injuries (eg falls, motor vehi-
cle accidents (MVA), sports injuries). Therefore, a
retrospective chart review was conducted through all the
patient charts that have been evaluated in the general neu-
rology clinic of two of the authors (WPP and MS) over the
previous 8 years. Headache type/injury source, gender, age
at clinic visit and concomitant thyroid disease were cap-
tured.
In order to minimize case ascertainment discrepancies
between the MS population sample and the general pop-
ulation sample, a followup electronic chart review was
performed on both the general and MS population cases.
As per the previous MS incidence and prevalence study,
complete physician billing records towards all thyroid dis-
ease and MS for the entire province were requested from
the provincial medical insurance plan via an official gov-
ernment Order in Council. This aided in the confirmation
of thyroid disease in both sample populations and mini-
mized the number of missed thyroid histories in the orig-
inal chart review. These billing records also increased
accuracy of case ascertainment and thus reduced referral
and ascertainment bias. Confirmation of thyroid disease
in both the MS population and the general population
sample was completed for all diagnoses via review of
patient charts and electronic records searching specifically
for thyroid stimulating hormone (TSH) receptor autoanti-
body tests, nuclear medicine studies, and diagnosis by an
endocrinologist or internist. Patients with MS were
excluded from the general population database and
patients from St Pierre et Miquelon, a neighbouring terri-
tory, were excluded from databases due to inconsistent
referral.
The diagnostic criteria used by endocrinologists for
Graves' disease has evolved over time[12]. All patients
with diagnosed Graves' disease in our study had increased
free thyroxine and decreased TSH. All patients were evalu-
ated using either 99 mTc radionucleotide scintigraphy or
131I uptake and scan. The diagnosis in some patients was
supported by positive TSH receptor autoantibodies.
Patients with Graves' disease were usually treated with
anti-thyroid drugs, and subsequent radioablation therapy
if required. The diagnosis of Hashimoto's disease was
based on low or low normal free T4 with elevated TSH,
and was supported by the presence of elevated anti-thy-
roperoxidase autoantibodies, and anti-thyroglobulin
autoantibodies. In addition, on clinical examination, a
firm goiter in the context of the aforementioned labora-
tory findings corroborated the diagnosis of Hashimoto's
disease. These patients were generally treated with thyroid
hormone replacement therapy.
Through initial sampling of patient charts, it was esti-
mated that a total of 500 patients would be found. For a
estimated prevalence of Hashimoto's thyroiditis of 2%
[13] (yielding 10 of 250 patients) and Graves' disease of
0.8% [13,14] (yielding 4 of 250 patients), it was decided
that this would not yield a large enough sample size to
give a clear indication of the demographics of thyroid dis-
ease in NL. Therefore, another retrospective chart review
was conducted in order to estimate the demographics of
Graves' and Hashimoto's disease. All the endocrinology
clinic patient charts of another author (CJ) were reviewed
from the previous 15 years to determine the demograph-
ics of patients in the province with (autoimmune) thyroid
disease not associated with either malignancy or specific
genetic syndromes such as Multiple Endocrine Neoplasia
II. Patient age at onset, disease type and gender were
recorded.
Comparison of prevalences between the MS and General
populations were performed both before and after direct
age and sex standardization of population samples. This
minimized bias due to different population distributions.
Two-tailed t tests were used for comparison of average age
of onset of disease. Chi squared tests were used to com-
pare proportions unless samples were less than 5, and
Fisher's exact test was used. An α of 0.05 was used for sig-
nificance.
Results
A previous MS prevalence study found 493 living patients
with MS in NL [11]. In October 2003, 438 addresses were
confirmed for a list of living MS patients [11] and these
patients were mailed surveys. After one survey mailing
and a followup mailing for non-responders, 328 surveys
were returned (a 75% rate of return). The results of this
survey are shown in Table 2. There were no significant dif-
Table 2: Patient characteristics of survey results.
All MS Patients Survey Returned Significance
Average Age 45.7 45.2 p = 0.53
Female to Male Ratio 2.72:1 2.86:1 p = 0.76
Age of First Symptoms 32.2 32.4 p = 0.81
Proportion RRMS 0.83 0.83 p = 0.97
RRMS – Relapsing Remitting Multiple SclerosisJournal of Autoimmune Diseases 2005, 2:9 http://www.jautoimdis.com/content/2/1/9
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ferences in demographics between the patients that
returned the surveys and the MS patients in the database.
532 patients with headache and various injuries were
found by chart review. The average age was 39.6 years and
the female to male ratio is 2.57:1. There were 274 patients
with migraines, 25 people with MVAs, 27 with injuries
and the rest were of various other headache types. The
prevalences of thyroid disease in both the MS population
and in our representative sample of the general popula-
tion are shown in Table 3. There was an increased preva-
lence of both Graves' disease and Hashimoto's disease in
the MS population compared to the general population,
although the co-occurrence of Hashimoto's was not sig-
nificant after age and sex standardization (Table 3).
Access to all provincial records made laboratory confirma-
tion of TSH results through electronic and hospital
records thorough. Of the 532 patients used for the repre-
sentative general population, 472 patients had recently
TSH results drawn within the past 9 years, most (433 –
81.4%) within 1 year of their neurology consultation or
since. In fact, many have had almost yearly serial TSH tests
performed for the past several years. We are unable to
speculate why this test appears to be so well-used in this
general patient population. Electronic and hospital
records were also used to confirm the use of thyroid
replacement medications as well as the results of ultra-
sound and nuclear medicine tests for diagnostic workup
of thyroid disease. Records of patient visits to endocrinol-
ogists were also available for this confirmation.
From the survey results, the chart reviews and the elec-
tronic record searches, 15 patients with Graves' disease
and 26 patients with Hashimoto's disease were found in
the MS population (Table 4). The age of onset of thyroid
disease was confirmed for all MS patients with concomi-
tant dysthyroidism. Neither the age of onset of thyroid
disease in the MS and general population nor the male to
female ratio were significantly different.
The age of onset (age at appearance of first symptoms) of
MS was confirmed for all MS patients with concomitant
thyroid disease and for all MS patients. The differences
between the age of onset of all MS patients and those MS
patients with both Graves' (p = 0.81) and Hashimoto's (p
= 0.71) was not significant.
Only 1 out of the 10 MS patients with Graves' disease that
responded completely on the survey had undertaken
treatment with an interferon-β prior to developing dysthy-
roidism which she had developed at 56 years of age, 1 year
after commencing therapy.
Discussion
Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system. It damages both oligoden-
droglia and axons and may cause paralysis, sensory distur-
bances, incoordination, visual impairment, and
alterations in autonomic and sexual function [15]. Its pre-
cise etiology has not been elucidated but many observa-
tions suggest that both genetic susceptibility and
environmental factors contribute [16]. There continues to
be a debate regarding the eligibility of MS as an autoim-
mune disease [17,18], although it is generally accepted as
such [19].
Hashimoto's thyroiditis is an organ-specific autoimmune
disease that is the most common cause of goitrous
hypothyroidism[20]. Identification as an autoimmune
disease follows observations that lymphocytes infiltrate
the thyroid [21] and autoantibodies against thyroglobu-
lin, thyroid peroxidase, and (rarely) thyroid hormone
stimulating receptor are found in patients with HT[20].
The initiation of the autoimmune events of HT are not
precisely known, but could be caused by a molecular
mimicry mechanism, abnormal antigen-specific induc-
tion of T-cells due to abnormal HLA-related SPC genes,
mutation of T cells to form abnormal clones, or an
immune defect causing reduced induction of T suppressor
cells by specific antigens [22].
Graves' disease is an autoimmune disorder characterized
by the production of thyroid-stimulating IgG immu-
noglobulins directed towards the thyroid simulating hor-
mone (TSH) receptor of the thyroid gland [23]. The exact
mechanism for the stimulation of these autoantibodies is
unknown, but several have been proposed [24].
Table 3: Prevalence of thyroid disease in MS patients and in a representative sample of the general population
MS Population
(N = 491)
General Population
(N = 532)
Significance after age-sex 
standardization
Graves' 15 (3.1%) 2 (0.4%) p = 0.002*
Hashimoto's 26 (5.5%) 12 (2.2%) p = 0.097
* by Fisher exact testJournal of Autoimmune Diseases 2005, 2:9 http://www.jautoimdis.com/content/2/1/9
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There is an increased risk of autoimmune thyroid disease
in patients with MS in Newfoundland and Labrador. The
study was comparably large (493 MS patients, 532 con-
trols) and there was an excellent survey response rate
(75%). There were no gender or age discrepancies in those
that responded to the survey (Table 2). Diagnostic confir-
mation was extensive and case ascertainment was compre-
hensive. Attempts to reduce reporting and ascertainment
bias were made.
Community surveys of hyperthyroidism due to Graves'
disease have reported prevalence rates of less than 1.9%,
but the prevalence can be as high as 2.7% if subclinical
cases are included [13]. Our study showed a rate of 0.38%
for Graves' disease (95% CI: 0.07–2.1%) which is compat-
ible with previously reported values. The prevalence of
hypothyroidism in other populations may be between
0.2% and 3% [13,25]. Our study showed a rate of 2.3%
(95% CI: 1.1–4.9%) in patients with MS, which is again
similar to those values reported elsewhere.
Other studies have demonstrated a high prevalence of
Graves' disease in first degree relatives of patients with MS
[2,7] but not with MS probands (in contrast to our study).
Since some MS patients treated with interferon-β may
develop laboratory signs of autoimmune thyroid disease
[8], it is important to determine whether disease modify-
ing drugs have caused this increased prevalence of Graves'
disease in our MS population.
Our survey asked questions relating to previous treatment
with disease modifying drugs and their initiation. Only 1
out of the 10 MS patients with Graves' disease that
responded completely on the survey had undertaken
treatment with an interferon-β prior to developing dysthy-
roidism which she had developed at 56 years of age, 1 year
after commencing therapy. It is unknown whether she
would have developed it without the interferon-β, but we
can test for significance while excluding her since it is
appropriate to look for co-occurrence once other avenues
of co-occurrence are factored out[5]. If one only includes
the 9 complete respondents via survey who either had not
even undertaken interferon-β therapy (N = 5) or had
begun therapy after the development of Graves' (N = 4),
there is still a significant proportion of MS patients with
Graves' disease (p = 0.024).
Although not as significant as the Graves' and MS co-
occurrence, the co-occurrence of MS with HT showed a
trend towards significance (p = 0.097). This confirms the
findings in two previous studies, both of them using lab-
oratory results to show an increase in serum TSH and
decrease in T3 and one also using serum autoantibodies
[3,6] although other large studies have failed to show an
increased risk of other autoimmune diseases (in particu-
lar, HT) in multiple sclerosis patients [2,26,27]. The retro-
spective case ascertainment of HT is most likely subject to
greater error than in the case of Graves' disease. Most
patients that returned surveys stated that they had primary
hypothyroidism, but did not state they had Hashimoto's
disease (Table 1). Most charts stated the same. The surveys
and charts of subjects with Graves' disease more specifi-
cally stated Graves' disease.
Our results suggest a link between autoimmune thyroid
disease and MS. There does not seem to be evidence for a
temporal link between the two conditions as the age of
onset of thyroid disease is the same in the general popula-
tion as in the MS population. As well, the age of onset of
MS is the same in subjects with and without thyroid dis-
ease. Therefore, this study does not provide evidence that
the onset of one disease is the harbinger of another.
The biological plausibility of an autoimmune pathophys-
iological link between MS and HT or Graves' disease is
unproven. Speculatively, MS is a disease characterized by
activated T cells. Activated T cells produce a milieu of
cytokines, notably IFN-γ. IFN-γ has been hypothesized to
induce the autoimmune process observed in Hashimoto's
disease. Therefore, the increased availability of activated T
cells in MS may cause an increase of Hashimoto's disease
in MS patients. The link between Graves' disease and MS
is less clear, however experimental observations using
Campath-1H may provide clues. Campath-1H is a mole-
cule that targets the CD52 antigens found on lymphocytes
and monocytes. It causes the immune response to change
Table 4: Demographics of MS patients with thyroid disease and demographics of patients with thyroid disease. Confirmed age means 
the number of MS patients whose age at onset of thyroid disease could be confirmed.
MS with Graves' Graves' Disease Significance MS with Hashimoto's Hashimoto's Significance
Total Number 15 80 26 57
Confirmed Age 10 13
Average Age of Onset of Thyroid Disease 35.2 37.5 p = 0.61 36.2 37.9 p = 0.70
Female:Male 13:2 72:8 p = 0.66* 21:5 48:9 p = 0.63
* by Fisher exact testPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Autoimmune Diseases 2005, 2:9 http://www.jautoimdis.com/content/2/1/9
Page 6 of 6
(page number not for citation purposes)
from the Th1 phenotype, thus suppressing MS disease
activity [28] but permitting the generation of antibody-
mediated thyroid autoimmunity. A significant increase in
the rate of development of Graves' disease in MS patients
was noted after treatment with Campath-1H [28], but
Graves' disease has not been reported in over 600 patients
treated with Campath-1H for various other autoimmune
disorders including rheumatoid arthritis and psoriasis
[28]. Further study along this direction may reveal the rea-
son for the increased co-occurrence between Graves' dis-
ease and Multiple Sclerosis.
Conclusion
Hashimoto's disease, Graves' disease and multiple sclero-
sis are autoimmune disorders that may share similar
mechanisms for the pathogenesis of the dysregulation of
their self immunity. This study has shown that there is a
significant co-occurrence in patients with MS and Graves'
disease, and a marginal co-occurrence in patients with MS
and HT disease. There appears to be no predilection for
earlier age of onset for either MS or the thyroid disorders
and there appears to be no gender preference in the co-
occurrence of the diseases. Reasons for their increased co-
occurrence are discussed.
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